The African Union (AU) has announced a deal that will send up to 400 million vaccines to 55 member states. The vaccines will go across the African continent in monthly shipments in order to fight the COVID-19 pandemic.
On August 5, 2021, Cyril Ramaphosa, the President of the Republic of South Africa made this historic vaccine rollout public. He reported that the AU had purchased 220 million doses of Johnson & Johnson’s COVID-19 vaccine in March. A possible 180 million additional vaccines can later be ordered.
How was the deal made?
In light of the COVID-19 pandemic, the African Union joined forces with the World Bank and other organizations to support The African Vaccine Acquisition Task Team. The team aims to provide rapid access to doses of the vaccine for the people of Africa. The team comprises ten members, including political leaders, health ministers, businessmen and philanthropists from all across Africa.
The World Bank will continue to support the AU in this historic vaccine rollout, supplying resources that will allow individual nations to purchase and distribute the vaccine. Additional assistance will come from the United Nations. UNICEF will assist with delivery and distribution management across the African continent.
Why Johnson & Johnson?
Each of the 400 million doses included in the deal will come from Johnson & Johnson.
The calculus behind this decision was thorough: Since the vaccine comes in a single dose, it is easier and cheaper to produce and administer. Moreover, the vaccine’s relatively long shelf life will ease logistical concerns. A recent study from South Africa reported high efficacy for the single-shot J&J vaccine, with up to 96.2 percent protection against death. The study also reported high protection against both the Delta and Beta variants of COVID-19 in Africa.
The most significant piece of the vaccine deal will take place right at home—part of the vaccine manufacturing process will occur in South Africa. Centralized at the Aspen Pharmacare facility in Gqeberha, South Africa, this insourcing of production will provide new jobs that will, in part, assist with post-pandemic economic recovery.
Where Africa Stands
As a continent, Africa lags behind in vaccination rates, which has placed economic stress on many nations. Vaccination rates also exemplify pandemic inequities that permeate the globe. As of July 23, 2021, only 2.2 percent of the African population has received a dose of any vaccine. In North America, more than half the population has received at least one shot.
These 400 million doses are enough to immunize more than one-third of the African population. At the same time, more work will need to take place in order for the continent to reach its 60% goal as it continues to adapt to and fight against the pandemic.
This new deal to bring in and produce vaccines provides hope that cases and deaths related to COVID-19 in Africa can decrease. It also helps cement the hope that even some of the most impoverished areas in Africa can recover from the pandemic.
– Sam Dils
Photo: Wikimedia Commons